Ultimately, multivariate analysis and a stepwise algorithm were used to ensure that the Akaike information criterion (AIC) is the minimum, thus a prognostic immune signature (PIS) consisting of 18 genes was constructed to predict the PFS of anti-PD-1 therapy in the treatment ccRCC. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.